Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 6
Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.
